Locus Biosciences

@LocusBio

Revolutionizing the treatment of bacterial disease.

RTP, North Carolina locus-bio.com Joined May 2013

367 Following 1.1K Followers 298 Posts

Latest posts 5

Pinned post

Locus Biosciences @LocusBio Jan 23, 2024

We’re thrilled to announce we've received funding from @BARDA to advance LBP-EC01, our first-in-class #CRISPR-engineered #bacteriophage therapy, into Part 2 of our Phase 2 ELIMINATE trial for treating #UTIs caused by drug-resistant E. coli.

Read more ➡️globenewswire.com/news-release/2…

Locus Biosciences @LocusBio Sep 10, 2024

With #AntibioticResistance on the rise, Locus is pioneering a new approach using bacteriophages to combat infections and other diseases like #IBD. Our AI-designed phage therapy selectively targets harmful bacteria. Read more about our efforts in @WIRED. wired.com/story/crispr-e…

www.wired.com Crispr-Enhanced Viruses Are Being Deployed Against UTIs With antibiotics losing their effectiveness, one company is turning to gene editing and bacteriophages—viruses that infect bacteria—to combat infections.

Locus Biosciences @LocusBio Aug 19, 2024

#ICYMI: Positive results from Part 1 of our Phase 2 ELIMINATE trial are published in The Lancet Infectious Diseases! LBP-EC01, our CRISPR-Cas3 engineered #bacteriophage, targets #UTIs caused by #AMR & #MDR E. coli. locus-bio.com/locus-bioscien…

Locus Biosciences @LocusBio Aug 14, 2024

Exciting news! Locus has been awarded $4.1M from @CARB_X to support the development of an engineered #bacteriophage therapy targeting infections caused by antimicrobial-resistant (#AMR) and multi-drug-resistant (#MDR) K. pneumoniae.

Locus Biosciences @LocusBio Aug 12, 2024

Positive results from Part 1 of our Phase 2 ELIMINATE trial evaluating genetically engineered bacteriophage therapy, LBP-EC01, to treat #UTIs were published in @TheLancet Infectious Diseases. Additionally, dosing has begun in Part 2 portion of this study. globenewswire.com/news-release/2…